Asia Pacific Biochips Market (2025-2030)
The Asia Pacific Biochips Market was valued at $3328.1 Million in 2025 and projected to reach to $5247.1 Million by 2030, representing a compound annual growth rate of 9.5%. The Asia Pacific biochips market is poised for substantial growth through 2030, driven by increasing healthcare expenditures, expanding middle-class populations, and government initiatives promoting biotechnology adoption.
| Market Size in | USD 26.32 MN |
| Market Forecast in | |
| CAGR | |
| Forecast Period | |
| Units Considered | Value (USD MN) |
Asia Pacific Biochips Market Trends and Insights
- Asia Pacific's biochips sector is driven by increasing healthcare investments, rising prevalence of chronic diseases, and growing adoption of personalized medicine across the region.
- The region's strong manufacturing capabilities and expanding biotechnology infrastructure position Asia Pacific as a critical hub for biochip innovation and commercialization. Asia Pacific's biochips market growth outpaces the global average, with a 9.5% compound annual growth rate significantly exceeding the global CAGR of 8.8%.
- This accelerated growth reflects Asia Pacific's demographic shifts, improving healthcare accessibility, and substantial government support for life sciences research.
- By 2030, Asia Pacific is expected to capture an increasingly larger share of the global biochips market, driven by technological advancement and rising demand for diagnostic and therapeutic applications throughout the region..
Key Market Statistics
- CAGR (2025-2030) 9.5% CAGR
- Market Size, 2025 ~USD 3328.1 Million
- Forecast, 2030 ~USD 5247.1 Million
- Geography Asia Pacific
Asia Pacific Biochips Market Overview
Rapid Market Expansion :
Asia Pacific biochips market is projected to grow from $3,328.1 million in 2025 to $5,247.1 million by 2030, representing a 9.5% CAGR, outpacing the global growth rate of 8.8%.
China's Market Leadership :
China dominates the Asia Pacific biochips sector with a market size of $2,022.9 million, driven by substantial government investments in biotechnology and advanced healthcare infrastructure development.
Chronic Disease Prevalence :
Rising incidence of chronic diseases across Asia Pacific nations is accelerating demand for diagnostic biochips and personalized medicine solutions, particularly in aging populations.
Manufacturing Excellence :
The region's robust semiconductor and biotech manufacturing capabilities position Asia Pacific as a global hub for biochip production, attracting significant foreign direct investment and innovation.
Asia Pacific Biochips Market Dynamics
- Countries like China, Japan, and India are investing heavily in research and development, creating favorable conditions for biochip innovation and commercialization. Personalized medicine adoption is accelerating across the region as healthcare systems modernize and patients demand more targeted diagnostic and therapeutic solutions.
- Strategic partnerships between regional manufacturers and global biochip companies, combined with improving regulatory frameworks, will further strengthen market penetration and drive the projected 9.5% CAGR through 2030..
Related Ecosystem
Advanced Genetic Sequencing
- Polymerase Chain Reaction (PCR)
- Reagents
- Assay Kits
- Bioinformatics
- Flow Cytometry
- Thermo Fisher Scientific Inc.
- Illumina, Inc.
- Agilent Technologies, Inc.
- Qiagen N.V.
- Danaher Corporation
Biotechnology
- Reagents
- Polymerase Chain Reaction (PCR)
- Stem Cells
- Assay Kits
- Flow Cytometers
- Thermo Fisher Scientific Inc.
- Merck KGaA
- Danaher Corporation
- Agilent Technologies, Inc.
- Bio-Rad Laboratories, Inc.
Key Takeaways
- Asia Pacific biochips market valued at $3,328.1M in 2025, expanding to $5,247.1M by 2030 at 9.5% CAGR
- Asia Pacific's growth rate of 9.5% exceeds global CAGR of 8.8%, reflecting regional market strength and opportunity
- Asia Pacific's biochips adoption driven by chronic disease prevalence, personalized medicine demand, and healthcare infrastructure investment
- Asia Pacific positioned as global manufacturing and innovation hub for biochips with strong government support and biotechnology ecosystem
Biochips Market Report Scope
| Report Metric | Details |
|---|---|
| Base Year | 2025 |
| Fastest Growing Segment | MICROFLUIDICS (Fabrication Technology) |
| Forecast Period | 2025–2030 |
| Growth Rate | CAGR of 8.8% from 2025 to 2030 |
| Largest Segment | MICROARRAYS (Fabrication Technology) |
| Market Size Base Year (Billions) | ~USD 14.01 (2025) |
| Revenue Forecast (Billions) | ~USD 21.36 (2030) |
| Segments Covered | Products & Services, Type, Application, Fabrication Technology, End User, Product & Service |
Asia Pacific Biochips Market Report Segmentation
6 segment dimensions are covered across the global market.
By Products & Services
- Consumables
- Instruments
- Software & Services
By Type
- Cell Arrays
- Dna Chips
- Lab-On-A-Chip
- Protein Chips
- Tissue Arrays
By Application
- Agricultural Biotechnology
- Cancer Diagnosis & Treatment
- Clinical Diagnostic
- Diagnostics
- Drug Discovery
- Expression Profiling
- Gene Expression
- Genomics
- High-Throughput Screening
- Ivd & Poc
- Other Dna Chip Applications
- Other Loac Applications
- Other Protein Chip Applications
- Proteomics
- Snp Genotyping
By Fabrication Technology
- Microarrays
- Microfluidics
By End User
- Academic & Research Institutes
- Biotechnology & Pharmaceutical Companies
- Contract Research Organizations
- Hospitals & Diagnostic Centers
- Other End Users
By Product & Service
- Consumables
- Instruments
- Software & Services
Target Audience
- Biochip Manufacturers : Manufacturers need Asia Pacific market data to identify expansion opportunities, assess competitive positioning, and develop region-specific product strategies aligned with local healthcare demands.
- Healthcare Investors : Investors require detailed market forecasts and country-level analysis to identify high-growth opportunities in Asia Pacific's biochips sector and optimize portfolio allocation decisions.
- Pharmaceutical Companies : Pharma firms need insights into personalized medicine adoption and diagnostic biochip integration opportunities across Asia Pacific to enhance drug development and companion diagnostic strategies.
- Healthcare Providers : Hospitals and diagnostic centers require market intelligence on biochip technologies, adoption trends, and cost-benefit analyses to inform procurement and service expansion decisions in Asia Pacific.
- Government and Policy Makers : Regulatory bodies and health ministries need comprehensive market data to develop biotechnology policies, allocate healthcare budgets, and support domestic biochips industry development across the region.
Key Companies in the Asia Pacific Biochips Market
| Company | HQ | Ownership | Strongest segments |
|---|---|---|---|
| ATS AUTOMATION TOOLING SYSTEMS INC | Canada | Public Company | Custom automated manufacturing and assembly systems,Pre- and post-automation services,Software and digital factory solutions, |
| DECODE GENETICS | Iceland | Private Company | Internal discovery and target validation for Amgen,External research collaborations and licensing,Population genomics and healthcare-linked projects, |
| JABIL | United States | Public Company | Regulated Industries (Healthcare, Automotive, Industrial, Packaging),Intelligent Infrastructure (5G, Cloud, Networking, Storage, Digital Building),Connected Living and Digital Commerce (Mobility, Connected Devices, Retail, Digital Commerce Ecosystem), |
| AT&S | Canada | Public Company | Turnkey automation systems (design, build, commissioning),Lifecycle services (pre- and post-automation, maintenance, retrofits),Contract manufacturing and integration, |
| X-FAB | Belgium | Public Company | Automotive analog & mixed-signal (incl. high-voltage, BCD, safety ICs),Power semiconductors (SiC, GaN, high-voltage discretes),MEMS & sensor platforms (pressure, inertial, image, gas/flow, photodiodes), |
| GE HEALTHCARE | United States | Public Company | Imaging,Advanced Visualization Solutions (AVS),Patient Care Solutions (PCS), |
| THERMO FISHER SCIENTIFIC INC. | United States | Public Company | Life Sciences Solutions,Analytical Instruments,Specialty Diagnostics, |
| ILLUMINA, INC. | United States | Public Company | Sequencing instruments,Sequencing consumables (reagents, flow cells, library prep, WGS and targeted kits),Array-based instruments and consumables, |
| AGILENT TECHNOLOGIES, INC. | United States | Public Company | Life Sciences and Diagnostics Markets,Agilent CrossLab,Applied Markets, |
| QIAGEN | Netherlands | Public Company | Sample technology consumables and instruments,Immune response (TB and transplant) assays,Oncology, sexual and reproductive health assays, |
| BIO-RAD LABORATORIES, INC. | United States | Public Company | Clinical Diagnostics systems, reagents, and quality controls,Life Science instruments and consumables for research and biopharma,Informatics and software solutions, |
| ABBOTT | United States | Public Company | Diagnostic Products,Medical Devices,Nutritional Products, |
| STANDARD BIOTOOLS | United States | Public Company | Proteomics platforms and consumables (SomaScan, CyTOF, Hyperion),Genomics platforms and consumables (Biomark X9 and qPCR systems),Services, software, and other, |
| 10X GENOMICS | United States | Public Company | Chromium instruments,Chromium consumables & kits (incl. QuantumScale),Visium spatial platform (instruments, slides, reagents), |
| CEPHEID | United States | Private Company | GeneXpert instruments,Xpert test cartridges (infectious disease & HAIs),Xpert test cartridges (virology, oncology, genetics), |
| BIOMéRIEUX | France | Public Company | Clinical microbiology (VITEK, BACT/ALERT, CHROMID, culture media, ETEST, API),Molecular diagnostics (BIOFIRE, SPOTFIRE, ARGENE, EMAG/NUCLISENS, EPISEQ),Immunoassay and sepsis markers (VIDAS, Hybiome CLIA), |
| REVVITY | United States | Public Company | Diagnostics & Immunodiagnostics (prenatal, newborn, infectious, autoimmune, specialty),Life Science Reagents & Assay Platforms,Genomic & NGS Workflow Solutions, |
| DIASORIN S.P.A. | Italy | Public Company | Immunodiagnostics (LIAISON XL / XS reagents and systems),Molecular diagnostics (Simplexa, LIAISON PLEX assays),xMAP technology and other specialty IVD solutions, |
ATS AUTOMATION TOOLING SYSTEMS INC
ATS Automation Tooling Systems Inc. is a Canadian public company founded in 1978 that employs 7,000 people. The company specializes in automation and tooling systems for industrial applications.
DECODE GENETICS
Decode Genetics is a private Icelandic company founded in 1996 with 331 employees. The company focuses on genetic research and analysis.
JABIL
Jabil is a large American public company founded in 1966 with 135,000 employees. The company provides electronics manufacturing services and solutions.
AT&S
AT&S is a Canadian public company founded in 1978 with 7,000 employees. The company specializes in automation and tooling systems.
X-FAB
X-FAB is a Belgian public semiconductor company founded in 1992 with 4,300 employees. The company manufactures specialty semiconductor products.
GE HEALTHCARE
GE Healthcare is an American public company founded in 2022 with 54,000 employees. The company provides medical imaging, diagnostics, and healthcare IT solutions.
THERMO FISHER SCIENTIFIC INC.
Thermo Fisher Scientific Inc. is a large American public company founded in 1956 with 125,000 employees. The company provides laboratory equipment, reagents, and services for research and diagnostics.
ILLUMINA, INC.
Illumina, Inc. is an American public company founded in 1998 with 8,625 employees. The company develops and manufactures DNA sequencing and genetic analysis systems.
AGILENT TECHNOLOGIES, INC.
Agilent Technologies, Inc. is an American public company founded in 1999 with 18,000 employees. The company provides analytical instruments and software for life sciences and diagnostics.
QIAGEN
Qiagen is a Dutch public company founded in 1984 with 5,500 employees. The company develops and manufactures molecular diagnostics and sample preparation products.
BIO-RAD LABORATORIES, INC.
Bio-Rad Laboratories, Inc. is an American public company founded in 1952 with 7,450 employees. The company manufactures and distributes life science research and clinical diagnostics products.
ABBOTT
Abbott is a large American public company founded in 1888 with 115,000 employees. The company develops and manufactures pharmaceuticals, diagnostics, and medical devices.
STANDARD BIOTOOLS
Standard Biotools is an American public company founded in 1999 with 387 employees. The company develops microfluidic and single-cell analysis solutions.
10X GENOMICS
10X Genomics is an American public company founded in 2012 with 1,178 employees. The company develops single-cell and spatial genomics solutions.
CEPHEID
Cepheid is an American private company founded in 1996 with 1,700 employees. The company manufactures molecular diagnostics and point-of-care testing systems.
BIOMéRIEUX
bioMérieux is a French public company founded in 1963 with 14,894 employees. The company develops and manufactures in vitro diagnostics and microbiology testing systems.
REVVITY
Revvity is an American public company founded in 1937 with 11,000 employees. The company provides analytical instruments, software, and services for life sciences and diagnostics.
DIASORIN S.P.A.
DiaSorin S.p.A. is an Italian public company founded in 1968 with 3,242 employees. The company develops and manufactures in vitro diagnostic products.
Countries within Asia Pacific - compare and drill down
| Country | 2025 size (native) |
|---|---|
| China | USD 2022.9 Million |
| Japan | USD 1158.6 Million |
| India | USD 806.6 Million |
| Australia | USD 273.3 Million |
| South Korea | USD 240 Million |
| Thailand | USD 144 Million |
| New Zealand | USD 113.2 Million |
| Rest Of Asia Pacific | USD 488.4 Million |
Country market size visualization
Reasons to Buy this Report
- Regional Market Segmentation : Gain detailed insights into country-specific biochips markets across Asia Pacific, including China, Japan, India, Australia, and South Korea, with granular data on market sizes and growth trajectories.
- Competitive Landscape Analysis : Understand key players, market consolidation trends, and competitive strategies specific to Asia Pacific, enabling informed investment and partnership decisions in the region.
- Growth Driver Identification : Identify region-specific growth catalysts including healthcare policy changes, chronic disease epidemiology, personalized medicine adoption rates, and manufacturing capabilities unique to Asia Pacific.
- Investment Opportunity Assessment : Evaluate high-potential markets and emerging opportunities within Asia Pacific with 9.5% CAGR projections, supporting strategic capital allocation and market entry planning.
- Regulatory and Market Access Insights : Access country-specific regulatory frameworks, reimbursement policies, and market access strategies essential for successful biochips commercialization across diverse Asia Pacific markets.
Frequently asked questions
What is the current size of the Asia Pacific biochips market?
The Asia Pacific biochips market is valued at $3,328.1 million in 2025 and is projected to grow to $5,247.1 million by 2030.
What is the growth rate of the Asia Pacific biochips market?
Asia Pacific's biochips market is growing at a compound annual growth rate (CAGR) of 9.5% from 2025 to 2030, outpacing the global average.
What factors are driving growth in Asia Pacific's biochips market?
Key drivers include rising chronic disease prevalence, increasing healthcare investments, growing adoption of personalized medicine, and expanding biotechnology infrastructure across Asia Pacific.
How does Asia Pacific's biochips market compare to the global market?
Asia Pacific's 9.5% CAGR exceeds the global CAGR of 8.8%, indicating the region is growing faster and gaining market share in the global biochips industry.
What is the forecast market size for Asia Pacific biochips by 2030?
The Asia Pacific biochips market is forecasted to reach $5,247.1 million by 2030, representing significant expansion from the 2025 baseline of $3,328.1 million.
RESEARCH METHODOLOGY
This research study extensively utilized both primary and secondary sources. It involved analyzing various factors influencing the industry to identify segmentation types, industry trends, key players, the competitive landscape, key market dynamics, and strategies employed by key players.
Secondary Research
This research study utilized a variety of comprehensive secondary sources, including directories, databases such as Bloomberg Business, Factiva, and Dun & Bradstreet, white papers, annual reports, company house documents, investor presentations, and SEC filings from various companies. Secondary research was employed to gather information crucial for an in-depth, technical, market-oriented, and commercial analysis of the biochips market. This approach also helped identify key players in the industry and allowed for classification and segmentation based on emerging trends at the most detailed level. Furthermore, significant developments pertaining to both market and technological perspectives were documented. A database of primary industry leaders was created as part of this secondary research.
Primary Research
In the primary research process, we interviewed a range of sources from both the supply and demand sides to gather qualitative and quantitative information for this report. Primary sources from the supply side include project/sales/marketing/business development managers, presidents, CEOs, vice presidents, chairpersons, chief operating officers, chief strategy officers, directors, chief information officers, and chief medical information officers related to the biochips market. Primary sources from the demand side include researchers in biotechnology and pharmaceutical companies, healthcare professionals from hospitals and diagnostic centers, academic & research institutes and contract research organizations.
A breakdown of the primary respondents is provided below:
Note 1: C-level executives include CEOs, COOs, CTOs, and VPs.
Note 2: Other designations include sales, marketing, and product managers.
Note 3: Tiers are defined based on a company’s total revenue. As of 2024: Tier 1 = >USD 1 billion, Tier 2 = USD 500 million to USD 1 billion, and Tier 3 = <USD 500 million.
To know about the assumptions considered for the study, download the pdf brochure
Market Size Estimation
The total size of the biochips market was determined after data triangulation from three approaches, as mentioned below. After each approach, the weighted average of the three approaches was taken based on the level of assumptions used in each approach.
Data Triangulation
After arriving at the market size, the total market was divided into several segments and subsegments. Data triangulation and market breakdown procedures were employed wherever applicable to complete the overall market engineering process and arrive at the exact statistics for all segments and subsegments.
Market Definition
The biochips market refers to miniaturized analytical platforms integrating biological probes or microfluidic components that allow simultaneous or rapid analysis of DNA, RNA, proteins, metabolites, or tissues. They are fabricated as microarrays, microfluidic cartridges, or tissue arrays and used in diagnostics, genomics, proteomics, drug discovery, and pathology research. These biochips enable high-throughput screening, providing faster, more efficient testing methods, and are critical in applications such as personalized medicine, disease detection, and environmental monitoring. With advances in technology, biochips are becoming increasingly versatile, supporting the development of novel diagnostics and therapeutic solutions across multiple sectors.
Stakeholders
- Pharmaceutical Companies
- Biotechnology Companies
- Research Institutes
- Academic Institutes
- Contract Research Organizations
- Research and Consulting Companies
- Biochip Manufacturers and Distributors
- DNA & Gene Chip Manufacturers and Distributors
- Protein Microarray Manufacturers and Distributors
- Lab-on-a-Chip Manufacturers and Distributors
- Cell & Tissue Array Manufacturers and Distributors
Report Objectives
- To define, describe, segment, and forecast the biochips market by products & services, type, fabrication technology, end user, and region
- To provide detailed information about the factors influencing market growth (such as drivers, restraints, opportunities, and challenges)
- To analyze micromarkets with respect to individual growth trends, prospects, and contributions to the overall biochips market
- To analyze market opportunities for stakeholders and provide details of the competitive landscape for key players
- To forecast the size of the biochips market in five main regions (along with their respective key countries): North America, Europe, the Asia Pacific, Latin America, and the Middle East & Africa
- To profile the key players in the biochips market and comprehensively analyze their core competencies and market shares
- To track and analyze competitive developments such as acquisitions, product launches, expansions, collaborations, agreements, and partnerships
Get the Full Biochips Market Report
Full forecast, segment splits, and company analysis for all Biochips Market.
- Canada Biochips Market
- US Biochips Market
- Germany Biochips Market
- UK Biochips Market
- France Biochips Market
- Italy Biochips Market
- Spain Biochips Market
- Netherlands Biochips Market
- China Biochips Market
- Japan Biochips Market
- India Biochips Market
- Australia Biochips Market
- South Korea Biochips Market
- Thailand Biochips Market
- New Zealand Biochips Market
- Brazil Biochips Market
- Mexico Biochips Market
- Rest Of Europe Biochips Market
- Rest Of Asia Pacific Biochips Market
- Rest Of Latin America Biochips Market
Need a Tailored Report?
Customize this report to your needs
Get 10% FREE Customization
Customize This Report
